Aptevo Therapeutics Inc. (APVO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today. Details Session Title: Bi and Multispecific Biologics Talk Title: Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform (talk being given as part of this session) Session Chair and Talk Presenter: Peter Pavlik, PhD Date/Time: Wednesday, January 15th from 3:15-5:20 US Pacific time.
Aptevo Therapeutics Inc. (APVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aptevo Therapeutics Inc. ever had a stock split?
Aptevo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey G. Lamothe CEO | NASDAQ (CM) Exchange | 03835L504 CUSIP |
| US Country | 37 Employees | - Last Dividend | 30 Dec 2025 Last Split | 20 Jul 2016 IPO Date |
Overview
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to the research and development of innovative immunotherapeutic treatments for cancer. Established in 2016 and headquartered in Seattle, Washington, Aptevo employs its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to craft monospecific, bispecific, and multi-specific antibody candidates. These candidates are designed to bolster the human immune system's ability to combat cancer cells, representing a frontier in medical science's ongoing battle against various forms of the disease. The company's dynamic research efforts underscore a commitment to addressing the complexities of cancer through the development of groundbreaking, targeted therapies.
Products and Services
- APVO436: This leading clinical candidate for blood cancer, specifically targeting acute myelogenous leukemia, is currently undergoing a Phase 1b/2 clinical trial. APVO436 epitomizes Aptevo’s approach to developing therapies that engage the body's immune system to fight cancer.
- ALG.APV-527: A novel bispecific ADAPTIR candidate, ALG.APV-527 is in Phase 1 clinical trials. It is aimed at treating non-small cell lung cancer (NSCLC), head and neck, colorectal, pancreatic, breast, and other solid tumors. Developed in collaboration with Alligator Bioscience AB, this investigational product highlights the potential of bispecific antibodies in targeting and neutralizing cancer cells.
- APVO603: Positioned as a preclinical dual agonist bispecific ADAPTIR candidate, APVO603 is designed for the treatment of multiple solid tumors. It showcases Aptevo’s dedication to expanding its portfolio with versatile therapeutic agents capable of addressing a wide range of cancers.
- APVO442: Utilizing the ADAPTIR-FLEX platform technology, APVO442 is a novel bispecific candidate currently in the development stage for multiple solid tumors. This candidate represents the next generation of Aptevo’s commitment to innovation in cancer therapy.
- APVO711: Still in the preclinical phase, APVO711 is a dual mechanism bispecific ADAPTIR candidate focused on treating prostate cancer. Highlighting the company’s exploration into specific cancer types, APVO711 aims to offer a new avenue for battling this prevalent disease.
